Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?

Abstract

For the Timed 25-Foot Walk (T25FW) and 9-Hole Peg Test (9HPT), components of the Multiple Sclerosis Functional Composite (MSFC), cut-off points of 20% change have previously been defined as meaningful endpoints of functional decline. Recently, however, a 15% change of MSFC components was introduced. The objective of this study was to determine optimal cut-offs for all MSFC components to indicate clinical disease progression in a primary progressive (PP) multiple sclerosis (MS) population. T25FW, 9HPT and the Paced Auditory Serial Addition Test (PASAT) were performed in 161 patients with PPMS with a 2-year interval. Absolute and relative differences in test scores were calculated. For each cut-off point of relative change, proportions of patients who progressed (deterioration beyond cut-off value) and improved (improvement beyond cut-off value) were calculated. Further, we calculated the ratio of ‘improved’ versus ‘progressed’ patients. Line graphs were created indicating: percentage progressed patients, percentage improved patients, and ratio of improved versus progressed patients. The optimal cut-off was determined by searching the cut-off point with the lowest ratio of improved versus progressed patients, while at the same time capturing a substantial amount of progression. For both T25FW and 9HPT, the ratio between patients that improved and worsened clearly decreased between the cut-offs of 15% and 20%. For the PASAT, the ratio between patients improved and worsened was persistently poor. In conclusion, a cut-off of 20% for both T25FW and 9HPT has a better signal-to-noise ratio than lower values (e.g. 15%) and is therefore preferable for the assessment of disease progression. No satisfactory cut-off point for the PASAT could be determined.

Keywords

9-Hole Peg Test multiple sclerosis Multiple Sclerosis Functional Composite outcome measurement Paced Auditory Serial Addition Test primary progressive Timed 25-Foot Walk

Get full access to this article

View all access options for this article.

References

Jacobs LD , Beck RW , Simon JH , et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.

Comi G. , Filippi M. , Barkhof F. , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582.

Kappos L. , Polman CH , Freedman MS , et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.

Johnson KP , Brooks BR , Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.

Comi G. , Filippi M. , Wolinsky JS European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.

Polman CH , O’Connor PW , Havrdova E. , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.

Rudick RA , Stuart WH , Calabresi PA , et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis . N Engl J Med 2006; 354: 911-923.

10.

Hobart J. , Freeman J. , Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000; 123: 1027-1040.

11.

Cutter GR , Baier ML , Rudick RA , et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999 ; 122: 871-882.

12.

Schwid SR , Goodman AD , McDermott MP , Bever CF , Cook SD

Quantitative functional measures in MS: what is a reliable change?

Neurology 2002; 58: 1294-1296.

13.

Hoogervorst EL , Kalkers NF , Cutter GR , Uitdehaag BM , Polman CH The patient’s perception of a (reliable) change in the Multiple Sclerosis Functional Composite . Mult Scler 2004; 10: 55-60.

14.

Kragt JJ , van der Linden FA , Nielsen JM , Uitdehaag BM , Polman CH Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006; 12: 594-598.

15.

Rudick R. , Polman C. , Cohen J. , et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 2009; 15: 984-997.

16.

Poser CM , Paty DW , Scheinberg L. , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.

17.

Bosma L. , Kragt J. , Brieva L. , et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler 2009; 15: 715-720.

18.

Lublin FD , Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.

19.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.

20.

Cohen JA , Cutter GR , Fischer JS , et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58: 961-967.

21.

Solari A. , Radice D. , Manneschi L. , Motti L. , Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 2005 ; 228: 71-74.

22.

Cohen JA , Fischer JS , Bolibrush DM , et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 2000; 54: 802-806.

23.

Drake AS , Weinstock-Guttman B. , Morrow SA , et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 2010; 16: 228-237.

24.

Huijbregts SC , Kalkers NF , de Sonneville LM , de Groot V. , Polman CH Cognitive impairment and decline in different MS subtypes. J Neurol Sci 2006; 245: 187-194.

25.

Bergendal G. , Fredrikson S. , Almkvist O. Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study. Eur Neurol 2007; 57: 193-202.

26.

Camp SJ , Stevenson VL , Thompson AJ , et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain 2005; 128: 2891-2898.